Smartphone App-Based Mindfulness Intervention for French and English Speaker Cancer Survivors
Cancer | PsychologicalThere is a need to develop, evaluate, and disseminate self-directed, easily accessible, safe, affordable, and effective psychosocial interventions to people living with cancer (PLWC) post-treatment. Smartphone app-based health interventions are an innovative way to deliver psychosocial cancer-care. The Mindfulness-Based Cancer Survivorship (MBCS) Journey app is a mobile app format of the Mindfulness-based Cancer Recovery program. In the SEAMLESS Study, the investigators aim to evaluate the MBCS Journey app (a 4 week mind-body intervention) in cancer survivors post-treatment. This is a randomized wait-list controlled trial. Participants will either be assigned into the immediate group (will receive intervention immediately after enrollment) or the waitlist group (wait for 3 months before receiving the intervention).
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
18 and up
Critères de participation
Inclusion Criteria:
* Adult ≥ 18 years
* Diagnosed with any type of cancer (stages I-IV)
* Completed primary treatment (i.e. surgery, chemotherapy, radiation therapy) at least 2 weeks (14days) prior. Note: ongoing maintenance therapy, hormone-blocking therapies, intermittent bone-modifying agents, herceptin and targeted therapy with trastuzumab are not exclusionary.
* Have access to a smartphone with data or wifi connection.
* Willing to devote 20-30 mins of time to mindfulness practices daily during the 4-week intervention period.
* Participant consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant must sign a consent form (e-consent) prior to enrollment in the study to document their willingness to participate.
* Participant is able (i.e. sufficiently fluent) and willing to complete the MBCS Journey and outcome measures in either English or French. The baseline assessment must be completed within required timelines, prior to randomization.
* In accordance with CCTG policy, protocol intervention is intended to begin within 7 calendar days of patient randomization.
* Participants must be willing to complete the MBCS Journey and complete the follow-up questionnaires
Exclusion Criteria:
* Major communication difficulties at the time of recruitment, as assessed by the research team (e.g. severe hearing impairment or cognitive impairment (score of ≤ 6; as assessed by the centre CRA using the three questions from the Brief Screen for Cognitive Impairment (BSCI)) listed in the screening CRF, which could interfere with completing the intervention and/or the questionnaires (i.e. inability to read or write)
* Suffering from untreated Major Depressive Disorder or other psychiatric disorders that would interfere with participation. (Note: Participants will be referred for treatment and invited to call back once in remission).
* Previous experience practicing in-person or app-based mindfulness once a week or more within the last year.
Lieu de l'étude
BCCA - Kelowna
BCCA - KelownaKelowna, British Columbia
Canada
Contactez l'équipe d'étude
Saroj Niraula
250 979-6650Western Manitoba Cancer Centre
Western Manitoba Cancer CentreBrandon, Manitoba
Canada
Contactez l'équipe d'étude
Arthur J.E. Child Comprehensive Cancer Centre
Arthur J.E. Child Comprehensive Cancer CentreCalgary, Alberta
Canada
Contactez l'équipe d'étude
BCCA - Victoria
BCCA - VictoriaVictoria, British Columbia
Canada
Contactez l'équipe d'étude
Caroline Holloway
250 519-5609BCCA - Prince George
BCCA - Prince GeorgePrince George, British Columbia
Canada
Contactez l'équipe d'étude
Irina Sainchuk
250 645-7300Horizon Health Network
Horizon Health NetworkFredericton, New Brunswick
Canada
Contactez l'équipe d'étude
M. Saleem Raza
506 447-4095Kingston Health Sciences Centre
Kingston Health Sciences CentreKingston, Ontario
Canada
Contactez l'équipe d'étude
April Swoboda
613 544-2361- Étude parrainée par
- Canadian Cancer Trials Group
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT05470010